Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety

Martin Schmelz, Patrick Mantyh, Anne Marie Malfait, John Farrar, Tony Yaksh, Leslie Tive, Lars Viktrup

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Chronic pain continues to be a significant global burden despite the availability of a variety of nonpharmacologic and pharmacologic treatment options. Thus, there is a need for new analgesics with novel mechanisms of action. In this regard, antibodies directed against nerve growth factor (NGF-Abs) are a new class of agents in development for the treatment of chronic pain conditions such as osteoarthritis and chronic low-back pain. This comprehensive narrative review summarizes evidence supporting pronociceptive functions for NGF that include contributing to peripheral and central sensitization through tropomyosin receptor kinase A activation and stimulation of local neuronal sprouting. The potential role of NGF in osteoarthritis and chronic low-back pain signaling is also examined to provide a mechanistic basis for the observed efficacy of NGF-Abs in clinical trials of these particular pain states. Finally, the safety profile of NGF-Abs in terms of common adverse events, joint safety, and nerve structure/function is discussed.

Original languageEnglish (US)
Pages (from-to)2210-2220
Number of pages11
JournalPain
Volume160
Issue number10
DOIs
StatePublished - Oct 1 2019

Fingerprint

Nerve Growth Factor
Low Back Pain
Chronic Pain
Osteoarthritis
Safety
Antibodies
Therapeutics
Central Nervous System Sensitization
Analgesics
Joints
Clinical Trials
Pain

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain : mechanism of action in the context of efficacy and safety. / Schmelz, Martin; Mantyh, Patrick; Malfait, Anne Marie; Farrar, John; Yaksh, Tony; Tive, Leslie; Viktrup, Lars.

In: Pain, Vol. 160, No. 10, 01.10.2019, p. 2210-2220.

Research output: Contribution to journalArticle

Schmelz, Martin ; Mantyh, Patrick ; Malfait, Anne Marie ; Farrar, John ; Yaksh, Tony ; Tive, Leslie ; Viktrup, Lars. / Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain : mechanism of action in the context of efficacy and safety. In: Pain. 2019 ; Vol. 160, No. 10. pp. 2210-2220.
@article{36f09b9c94b14e06b82fb3d8b36b7e53,
title = "Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety",
abstract = "Chronic pain continues to be a significant global burden despite the availability of a variety of nonpharmacologic and pharmacologic treatment options. Thus, there is a need for new analgesics with novel mechanisms of action. In this regard, antibodies directed against nerve growth factor (NGF-Abs) are a new class of agents in development for the treatment of chronic pain conditions such as osteoarthritis and chronic low-back pain. This comprehensive narrative review summarizes evidence supporting pronociceptive functions for NGF that include contributing to peripheral and central sensitization through tropomyosin receptor kinase A activation and stimulation of local neuronal sprouting. The potential role of NGF in osteoarthritis and chronic low-back pain signaling is also examined to provide a mechanistic basis for the observed efficacy of NGF-Abs in clinical trials of these particular pain states. Finally, the safety profile of NGF-Abs in terms of common adverse events, joint safety, and nerve structure/function is discussed.",
author = "Martin Schmelz and Patrick Mantyh and Malfait, {Anne Marie} and John Farrar and Tony Yaksh and Leslie Tive and Lars Viktrup",
year = "2019",
month = "10",
day = "1",
doi = "10.1097/j.pain.0000000000001625",
language = "English (US)",
volume = "160",
pages = "2210--2220",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "10",

}

TY - JOUR

T1 - Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain

T2 - mechanism of action in the context of efficacy and safety

AU - Schmelz, Martin

AU - Mantyh, Patrick

AU - Malfait, Anne Marie

AU - Farrar, John

AU - Yaksh, Tony

AU - Tive, Leslie

AU - Viktrup, Lars

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Chronic pain continues to be a significant global burden despite the availability of a variety of nonpharmacologic and pharmacologic treatment options. Thus, there is a need for new analgesics with novel mechanisms of action. In this regard, antibodies directed against nerve growth factor (NGF-Abs) are a new class of agents in development for the treatment of chronic pain conditions such as osteoarthritis and chronic low-back pain. This comprehensive narrative review summarizes evidence supporting pronociceptive functions for NGF that include contributing to peripheral and central sensitization through tropomyosin receptor kinase A activation and stimulation of local neuronal sprouting. The potential role of NGF in osteoarthritis and chronic low-back pain signaling is also examined to provide a mechanistic basis for the observed efficacy of NGF-Abs in clinical trials of these particular pain states. Finally, the safety profile of NGF-Abs in terms of common adverse events, joint safety, and nerve structure/function is discussed.

AB - Chronic pain continues to be a significant global burden despite the availability of a variety of nonpharmacologic and pharmacologic treatment options. Thus, there is a need for new analgesics with novel mechanisms of action. In this regard, antibodies directed against nerve growth factor (NGF-Abs) are a new class of agents in development for the treatment of chronic pain conditions such as osteoarthritis and chronic low-back pain. This comprehensive narrative review summarizes evidence supporting pronociceptive functions for NGF that include contributing to peripheral and central sensitization through tropomyosin receptor kinase A activation and stimulation of local neuronal sprouting. The potential role of NGF in osteoarthritis and chronic low-back pain signaling is also examined to provide a mechanistic basis for the observed efficacy of NGF-Abs in clinical trials of these particular pain states. Finally, the safety profile of NGF-Abs in terms of common adverse events, joint safety, and nerve structure/function is discussed.

UR - http://www.scopus.com/inward/record.url?scp=85070686260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070686260&partnerID=8YFLogxK

U2 - 10.1097/j.pain.0000000000001625

DO - 10.1097/j.pain.0000000000001625

M3 - Article

C2 - 31145219

AN - SCOPUS:85070686260

VL - 160

SP - 2210

EP - 2220

JO - Pain

JF - Pain

SN - 0304-3959

IS - 10

ER -